On December 22, 2021, FDA took another step in rolling back enforcement policies implemented in response to the COVID-19 pandemic by publishing guidance documents describing the regulatory requirements for devices that were authorized under the emergency use authorization process and those under temporary FDA policies implementing specific enforcement discretion during the pandemic once the Public Health Emergency for COVID-19 ends. The Transition Plan Guidances will help device manufacturers prepare for the end of the PHE and continue to commercialize devices necessary for the long-term response to COVID-19.Learn More
The deal will take public ProKidney, a leading clinical-stage cellular therapeutics company focused on chronic kidney disease, and is expected to provide up to $825 million in gross cash proceeds.Learn More
Mintz Advises BeiGene in Agreement with Novartis to Develop & Commercialize BeiGene TIGIT Inhibitor & Market Novartis Meds in China
Mintz and Licensing & Collaborations Practice Member John Cheney have represented BeiGene in numerous licensing transactions, including strategic collaborations with Amgen, Mirati Therapeutics, and Celgene, among others.Learn More
Mintz advised acute health care services and specialty hospital company Kindred Healthcare and private equity firm TPG Capital in the sale of Kindred Healthcare to LifePoint Health, a national hospital and health care services provider. The combined company, ScionHealth, operates 79 hospital campuses in 25 states.Learn More
Awards and Recognition
Best Law Firms 2022
U.S. News & World Report and Best Lawyers
The firm received 59 top-tier national and regional rankings in the 2022 edition.
Mintz ranks among the top 100 US law firms in terms of gross revenue.
Chambers USA 2021
The 2021 edition recognized 69 Mintz attorneys and 19 of the firm’s practices as leaders in their field.
Best Places to Work for LGBT Equality 2021
Human Rights Campaign Foundation
Mintz received its 14th consecutive perfect score on the annual Corporate Equality Index.